Combining a targeted drug with hormone therapy substantially extends survival for women with advanced breast cancer, a major clinical trial has found.

A drug used in treating non-small cell lung cancer could offer a new targeted therapy for thousands of breast cancer patients, following the discovery that it can kill breast cancer cells with a particular genetic defect.

An ICR researcher has been given a prestigious award at the San Antonio Breast Cancer Symposium, one of the world’s most important annual breast cancer research conferences.